{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:02:25Z","timestamp":1787068945213,"version":"build-2736575974"},"reference-count":103,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Background\/Objectives: CTLA-4 is a key checkpoint of peripheral immune regulation, yet its biology cannot be reduced to inhibitory signaling alone. This review discusses CTLA-4 as a dynamic regulatory pathway shaped by ligand handling, intracellular trafficking, recycling, and cell-type-specific function, and examines how these features link molecular mechanism to human disease and therapy. Methods: We synthesized the structural, mechanistic, translational, and clinical literature spanning CTLA-4 molecular biology, cell-type-specific function, inborn errors of immunity, polygenic autoimmunity, transplantation, cancer immunotherapy, and immune-related adverse events. Results: CTLA-4 function depends on surface availability, trans-endocytosis of CD80\/CD86, and tight control of endosomal trafficking. These features help explain why CTLA-4 haploinsufficiency, LRBA deficiency, and DEF6 deficiency converge clinically despite different upstream lesions, and why subtler CTLA-4 variation contributes to polygenic autoimmunity. Therapeutic studies also provide mechanistic insight. Abatacept can partly replace pathway function in monogenic disease, whereas belatacept highlights the limits of ligand blockade when endogenous coinhibition is also lost. In oncology, anti-CTLA-4 antibodies act through a more complex interplay involving checkpoint blockade, Fc biology, intratumoral Treg depletion, and receptor recycling. Emerging next-generation agents aim to retain antitumor activity while reducing systemic toxicity through more selective use of these mechanisms. Conclusions: Rather than a static inhibitory receptor, CTLA-4 is better viewed as a context-dependent regulatory pathway whose function depends on trafficking, surface availability, and cellular context. This perspective links molecular mechanism to clinical phenotype and supports more precise CTLA-4-targeted therapy.<\/jats:p>","DOI":"10.3390\/genes17050574","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:45:34Z","timestamp":1779291934000},"page":"574","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The CTLA-4 Pathway in Human Disease: Molecular Mechanisms and Therapeutic Targeting"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1267-4320","authenticated-orcid":false,"given":"Simone","family":"Negrini","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, University of Turin, 10124 Turin, Italy"},{"name":"Immunology and Allergy Unit, AO Ordine Mauriziano di Torino, 10128 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Nicola","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Turin, 10124 Turin, Italy"},{"name":"Immunology and Allergy Unit, AO Ordine Mauriziano di Torino, 10128 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8364-6023","authenticated-orcid":false,"given":"Iuliana","family":"Badiu","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Turin, 10124 Turin, Italy"},{"name":"Immunology and Allergy Unit, AO Ordine Mauriziano di Torino, 10128 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7679-2372","authenticated-orcid":false,"given":"Anna","family":"Quinternetto","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Turin, 10124 Turin, Italy"},{"name":"Immunology and Allergy Unit, AO Ordine Mauriziano di Torino, 10128 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Vitali","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Turin, 10124 Turin, Italy"},{"name":"Immunology and Allergy Unit, AO Ordine Mauriziano di Torino, 10128 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca Lo","family":"Sardo","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Turin, 10124 Turin, Italy"},{"name":"Immunology and Allergy Unit, AO Ordine Mauriziano di Torino, 10128 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7249-7616","authenticated-orcid":false,"given":"Luisa","family":"Brussino","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Turin, 10124 Turin, Italy"},{"name":"Immunology and Allergy Unit, AO Ordine Mauriziano di Torino, 10128 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/35069118","article-title":"Crystal structure of the B7-1\/CTLA-4 complex that inhibits human immune responses","volume":"410","author":"Stamper","year":"2001","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/35069112","article-title":"Structural basis for co-stimulation by the human CTLA-4\/B7-2 complex","volume":"410","author":"Schwartz","year":"2001","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"15417","DOI":"10.1074\/jbc.270.25.15417","article-title":"Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4). A disulfide-linked homodimer binds two CD86 molecules","volume":"270","author":"Linsley","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1084\/jem.185.3.393","article-title":"CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics","volume":"185","author":"Bodian","year":"1997","journal-title":"J. Exp. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1074-7613(02)00362-X","article-title":"The interaction properties of costimulatory molecules revisited","volume":"17","author":"Collins","year":"2002","journal-title":"Immunity"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.1074\/jbc.M110.182394","article-title":"Rigid-body ligand recognition drives cytotoxic T-lymphocyte antigen 4 (CTLA-4) receptor triggering","volume":"286","author":"Yu","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"E4223","DOI":"10.1073\/pnas.1617941114","article-title":"Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab","volume":"114","author":"Ramagopal","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Siggs, O.M., Russell, A., Singh-Grewal, D., Wong, M., Chan, P., Craig, M.E., O\u2019Loughlin, T., Stormon, M., and Goodnow, C.C. (2019). Preponderance of CTLA4 variation associated with autosomal dominant immune dysregulation in the MYPPPY motif. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01544"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.4049\/jimmunol.181.3.1806","article-title":"CTLA4 expression is an indicator and regulator of steady-state CD4+FoxP3+ T cell homeostasis","volume":"181","author":"Tang","year":"2008","journal-title":"J. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1002\/eji.200324632","article-title":"Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA-4 expression","volume":"34","author":"Birebent","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.4049\/jimmunol.181.3.1683","article-title":"Acquisition of suppressive function by activated human CD4+CD25\u2212 T cells is associated with the expression of CTLA-4, not FoxP3","volume":"181","author":"Zheng","year":"2008","journal-title":"J. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/gene.2013.57","article-title":"Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation","volume":"15","author":"Chan","year":"2014","journal-title":"Genes Immun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1074-7613(00)80480-X","article-title":"Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement","volume":"4","author":"Linsley","year":"1996","journal-title":"Immunity"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"9273","DOI":"10.1073\/pnas.94.17.9273","article-title":"Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein","volume":"94","author":"Zhang","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1074-7613(00)80346-5","article-title":"Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2","volume":"6","author":"Shiratori","year":"1997","journal-title":"Immunity"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"9429","DOI":"10.1074\/jbc.M111.304329","article-title":"Constitutive clathrin-mediated endocytosis of CTLA-4 persists during T cell activation","volume":"287","author":"Qureshi","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.4049\/jimmunol.163.4.1868","article-title":"Cytolytic T lymphocyte-associated antigen-4 and the TCR\/CD3 complex, but not CD28, interact with clathrin adaptor complexes AP-1 and AP-2","volume":"163","author":"Schneider","year":"1999","journal-title":"J. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1084\/jem.20011868","article-title":"Surface cytotoxic T lymphocyte-associated antigen 4 partitions within lipid rafts and relocates to the immunological synapse under conditions of inhibition of T cell activation","volume":"195","author":"Darlington","year":"2002","journal-title":"J. Exp. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.aaa1663","article-title":"Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy","volume":"349","author":"Lo","year":"2015","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/imm.13343","article-title":"Regulation of CTLA-4 recycling by LRBA and Rab11","volume":"164","author":"Janman","year":"2021","journal-title":"Immunology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1038\/s41467-019-10812-x","article-title":"Human DEF6 deficiency underlies an immunodeficiency syndrome with systemic autoimmunity and aberrant CTLA-4 homeostasis","volume":"10","author":"Serwas","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"G\u00e1mez-D\u00edaz, L., and Seidel, M.G. (2021). Different apples, same tree: Visualizing current biological and clinical insights into CTLA-4 insufficiency and LRBA and DEF6 deficiencies. Front. Pediatr., 9.","DOI":"10.3389\/fped.2021.662645"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: A molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.4049\/jimmunol.1401876","article-title":"A transendocytosis model of CTLA-4 function predicts its suppressive behavior on regulatory T cells","volume":"194","author":"Hou","year":"2015","journal-title":"J. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"eaaw0902","DOI":"10.1126\/sciimmunol.aaw0902","article-title":"CTLA-4-mediated transendocytosis of costimulatory molecules primarily targets migratory dendritic cells","volume":"4","author":"Ovcinnikovs","year":"2019","journal-title":"Sci. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e2023739118","DOI":"10.1073\/pnas.2023739118","article-title":"Treg-expressed CTLA-4 depletes CD80\/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells","volume":"118","author":"Tekguc","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41590-022-01289-w","article-title":"Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation","volume":"23","author":"Kennedy","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Halliday, N., Williams, C., Kennedy, A., Waters, E., Pesenacker, A.M., Soskic, B., Hinze, C., Hou, T.Z., Rowshanravan, B., and Janman, D. (2020). CD86 Is a Selective CD28 Ligand Supporting FoxP3+ Regulatory T Cell Homeostasis in the Presence of High Levels of CTLA-4. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.600000"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1126\/science.aav7062","article-title":"Restriction of PD-1 function by cis-PD-L1\/CD80 interactions is required for optimal T cell responses","volume":"364","author":"Sugiura","year":"2019","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.immuni.2019.11.003","article-title":"PD-L1:CD80 cis-heterodimer triggers the co-stimulatory receptor CD28 while repressing the inhibitory PD-1 and CTLA-4 pathways","volume":"51","author":"Zhao","year":"2019","journal-title":"Immunity"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e111556","DOI":"10.15252\/embj.2022111556","article-title":"The CTLA-4 immune checkpoint protein regulates PD-L1:PD-1 interaction via transendocytosis of its ligand CD80","volume":"42","author":"Kennedy","year":"2023","journal-title":"EMBO J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"114768","DOI":"10.1016\/j.celrep.2024.114768","article-title":"Rigid, bivalent CTLA-4 binding to CD80 is required to disrupt the cis CD80\/PD-L1 interaction","volume":"43","author":"Robinson","year":"2024","journal-title":"Cell Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1006\/cimm.2000.1649","article-title":"A native soluble form of CTLA-4","volume":"201","author":"Oaks","year":"2000","journal-title":"Cell. Immunol."},{"key":"ref_34","first-page":"336","article-title":"The soluble CTLA-4 receptor: A new marker in autoimmune diseases","volume":"53","author":"Pawlak","year":"2005","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s13317-010-0011-7","article-title":"The soluble CTLA-4 receptor and its role in autoimmune diseases: An update","volume":"1","author":"Saverino","year":"2010","journal-title":"Autoimmun. Highlights"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"215763","DOI":"10.1155\/2014\/215763","article-title":"The soluble form of CTLA-4 from serum of patients with autoimmune diseases regulates T-cell responses","volume":"2014","author":"Simone","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13075-016-1075-1","article-title":"Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus","volume":"18","author":"Dahal","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.2337\/db11-0130","article-title":"The soluble CTLA-4 splice variant protects from type 1 diabetes and potentiates regulatory T-cell function","volume":"60","author":"Gerold","year":"2011","journal-title":"Diabetes"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.immuni.2025.03.004","article-title":"Soluble CTLA-4 regulates immune homeostasis and promotes resolution of inflammation by suppressing type 1 but allowing type 2 immunity","volume":"58","author":"Osaki","year":"2025","journal-title":"Immunity"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1073\/pnas.0910341107","article-title":"Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity","volume":"107","author":"Jain","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nm.2425","article-title":"Foxp3+ follicular regulatory T cells control the germinal center response","volume":"17","author":"Linterman","year":"2011","journal-title":"Nat. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.4049\/jimmunol.1101328","article-title":"Regulation of the germinal center reaction by Foxp3+ follicular regulatory T cells","volume":"187","author":"Wollenberg","year":"2011","journal-title":"J. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.immuni.2014.12.006","article-title":"Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4","volume":"41","author":"Wing","year":"2014","journal-title":"Immunity"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.immuni.2014.12.005","article-title":"The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells","volume":"41","author":"Sage","year":"2014","journal-title":"Immunity"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"E6400","DOI":"10.1073\/pnas.1705551114","article-title":"A distinct subpopulation of CD25\u2212 T follicular regulatory cells localizes in the germinal centers","volume":"114","author":"Wing","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.4049\/jimmunol.1200972","article-title":"Cutting edge: Cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells","volume":"189","author":"Wang","year":"2012","journal-title":"J. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.4049\/jimmunol.1200695","article-title":"Cutting edge: CTLA-4 on effector T cells inhibits in trans","volume":"189","author":"Corse","year":"2012","journal-title":"J. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/eji.200838770","article-title":"CD152 (CTLA-4) regulates effector functions of CD8+ T lymphocytes by repressing Eomesodermin","volume":"39","author":"Hegel","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1084\/jem.189.7.1157","article-title":"Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8+ T cells independently of CD4+ T cell help","volume":"189","author":"McCoy","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"E2223","DOI":"10.1073\/pnas.1209115109","article-title":"Activated T cell CTLA-4 regulates T cell differentiation via the Hippo pathway","volume":"109","author":"Thaventhiran","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1128\/JVI.80.1.270-280.2006","article-title":"Lack of intrinsic CTLA-4 expression has minimal effect on regulation of antiviral T-cell immunity","volume":"80","author":"Homann","year":"2006","journal-title":"J. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.immuni.2015.05.023","article-title":"Quiescence of memory CD8+ T cells is mediated by regulatory T cells through inhibitory receptor CTLA-4","volume":"42","author":"Kalia","year":"2015","journal-title":"Immunity"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.jaci.2023.08.004","article-title":"Therapeutic modalities and clinical outcomes in a large cohort with LRBA deficiency and CTLA4 insufficiency","volume":"152","author":"Taghizade","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1126\/science.1255904","article-title":"Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4","volume":"345","author":"Kuehn","year":"2014","journal-title":"Science"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/nm.3746","article-title":"Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations","volume":"20","author":"Schubert","year":"2014","journal-title":"Nat. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.jaci.2018.02.055","article-title":"Phenotype, penetrance, and treatment of 133 CTLA-4-insufficient subjects","volume":"142","author":"Schwab","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/cei.13600","article-title":"A comprehensive comparison between 222 patients with LRBA deficiency and 212 patients with CTLA4 insufficiency: A systematic review","volume":"205","author":"Jamee","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/ACI.0000000000001117","article-title":"CTLA4-related primary immune dysregulatory disorders","volume":"25","year":"2025","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.jaci.2019.12.896","article-title":"Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score","volume":"145","author":"Tesch","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaci.2021.04.039","article-title":"Therapeutic options for CTLA-4 insufficiency","volume":"149","author":"Egg","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.jaci.2024.08.020","article-title":"Hematopoietic stem cell transplantation for CTLA-4 insufficiency across Europe: A European Society for Blood and Marrow Transplantation Inborn Errors Working Party study","volume":"154","author":"Tsilifis","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature01621","article-title":"Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease","volume":"423","author":"Ueda","year":"2003","journal-title":"Nature"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.gene.6364211","article-title":"A common autoimmunity predisposing signal in the 3\u2032 untranslated region of CTLA4 does not affect mRNA stability or splicing in human cells","volume":"6","author":"Anjos","year":"2005","journal-title":"Genes Immun."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1210\/jc.2007-0147","article-title":"Cytotoxic T-lymphocyte associated antigen 4 gene polymorphisms and susceptibility to autoimmune thyroid disease: A meta-analysis","volume":"92","author":"Kavvoura","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Wang, J., Liu, L., Ma, J., Sun, F., Zhao, Z., and Gu, M. (2014). Common Variants on Cytotoxic T Lymphocyte Antigen-4 Polymorphisms Contributes to Type 1 Diabetes Susceptibility: Evidence Based on 58 Studies. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0085982"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1089\/dna.2010.1021","article-title":"CTLA4 CT60 single-nucleotide polymorphism is associated with Slovenian inflammatory bowel disease and regulates expression of CTLA4 isoforms","volume":"29","author":"Repnik","year":"2010","journal-title":"DNA Cell Biol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"18607","DOI":"10.1073\/pnas.0706409104","article-title":"Allelic variant in CTLA4 alters T cell phosphorylation patterns","volume":"104","author":"Maier","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am. J. Transplant."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1111\/ajt.13830","article-title":"A phase III study of belatacept versus cyclosporine in kidney transplant recipients from extended criteria donors (BENEFIT-EXT study). Final seven-year results","volume":"16","author":"Durrbach","year":"2016","journal-title":"Am. J. Transplant."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/j.1600-6143.2011.03929.x","article-title":"Deleterious effect of CTLA-4-Ig on a Treg-dependent transplant model","volume":"12","author":"Riella","year":"2012","journal-title":"Am. J. Transplant."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1111\/j.1600-6143.2008.02377.x","article-title":"The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation","volume":"8","author":"Bluestone","year":"2008","journal-title":"Am. J. Transplant."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1681\/ASN.2015070774","article-title":"Anti-CD28 antibody and belatacept exert differential effects on mechanisms of renal allograft rejection","volume":"27","author":"Ville","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"17ra10","DOI":"10.1126\/scitranslmed.3000116","article-title":"Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation","volume":"2","author":"Poirier","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/ajt.12964","article-title":"FR104, an antagonist anti-CD28 monovalent Fab\u2032 antibody, prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate kidney transplantation","volume":"15","author":"Poirier","year":"2015","journal-title":"Am. J. Transplant."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1097\/TP.0000000000002740","article-title":"Selective CD28 antagonists in organ transplantation","volume":"103","author":"Vanhove","year":"2019","journal-title":"Transplantation"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J. Exp. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ccell.2018.02.010","article-title":"Fc effector function contributes to the activity of human anti-CTLA-4 antibodies","volume":"33","author":"Furness","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e2300895120","DOI":"10.1073\/pnas.2300895120","article-title":"Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies","volume":"120","author":"Lax","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1158\/2159-8290.CD-24-0190","article-title":"Botensilimab, an Fc-enhanced anti-CTLA-4 antibody, is effective against tumors poorly responsive to conventional immunotherapy","volume":"14","author":"Chand","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41422-019-0184-1","article-title":"Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy","volume":"29","author":"Zhang","year":"2019","journal-title":"Cell Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2017.07.014","article-title":"Lessons from CTLA-4 deficiency and checkpoint inhibition","volume":"49","author":"Lo","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.imbio.2014.11.019","article-title":"Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiency","volume":"220","author":"Mehrishi","year":"2015","journal-title":"Immunobiology"},{"key":"ref_86","first-page":"A1378","article-title":"1246 Immune related adverse events to checkpoint inhibitors are associated with altered regulatory T cell phenotypes and resemble CTLA4-deficient patients","volume":"11","author":"Maiarana","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: Insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am. J. Pathol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.4049\/jimmunol.164.10.5015","article-title":"Cutting Edge: A soluble form of CTLA-4 in patients with autoimmune thyroid disease","volume":"164","author":"Oaks","year":"2000","journal-title":"J. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/ajt.14349","article-title":"Belatacept-resistant rejection is associated with CD28+ memory CD8 T cells","volume":"17","author":"Mathews","year":"2017","journal-title":"Am. J. Transplant."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","article-title":"A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention","volume":"11","author":"Wei","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"eabm5663","DOI":"10.1126\/scitranslmed.abm5663","article-title":"Soluble CTLA-4 mutants ameliorate immune-related adverse events but do not compromise cancer immunotherapy","volume":"15","author":"Liu","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"101008","DOI":"10.1016\/j.conctc.2022.101008","article-title":"The ABACHAI clinical trial protocol: Safety and efficacy of abatacept (s.c.) in patients with CTLA-4 insufficiency or LRBA deficiency: A non-controlled phase 2 clinical trial","volume":"30","author":"Krausz","year":"2022","journal-title":"Contemp. Clin. Trials Commun."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jaci.2014.10.019","article-title":"Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA","volume":"135","author":"Charbonnier","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.jaci.2017.05.022","article-title":"Exaggerated follicular helper T-cell responses in patients with LRBA deficiency due to failure of CTLA4-mediated regulation","volume":"141","author":"Alroqi","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.jaci.2025.08.027","article-title":"Abatacept restores dysregulated transcriptomic and proteomic profile in disorders of CTLA-4 insufficiency","volume":"156","author":"Catak","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e2422731122","DOI":"10.1073\/pnas.2422731122","article-title":"pH-dependent dissociation from CTLA-4 in early endosomes improves both safety and antitumor activity of anti-CTLA-4 antibodies","volume":"122","author":"Zhang","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2024642","DOI":"10.1080\/19420862.2021.2024642","article-title":"Improved therapeutic index of an acidic pH-selective antibody","volume":"14","author":"Lee","year":"2022","journal-title":"mAbs"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41421-020-00202-9","article-title":"Crystal structure of CTLA-4 complexed with the pH-dependent cancer immunotherapy antibody HL32","volume":"6","author":"Gao","year":"2020","journal-title":"Cell Discov."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"102141","DOI":"10.1016\/j.xcrm.2025.102141","article-title":"Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade","volume":"6","author":"Blanchard","year":"2025","journal-title":"Cell Rep. Med."},{"key":"ref_102","first-page":"A998","article-title":"949 First-in-human study of the first acid pH-sensitive and recycling CTLA-4 antibody ONC-392","volume":"9","author":"Li","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Smith, F.D., Pierce, R.H., Thisted, T., and van der Horst, E.H. (2023). Conditionally Active, pH-Sensitive Immunoregulatory Antibodies Targeting VISTA and CTLA-4 Lead an Emerging Class of Cancer Therapeutics. Antibodies, 12.","DOI":"10.3390\/antib12030055"}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/5\/574\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:54:09Z","timestamp":1779292449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/5\/574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":103,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["genes17050574"],"URL":"https:\/\/doi.org\/10.3390\/genes17050574","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]}}}